185 related articles for article (PubMed ID: 27864876)
1. Kinase gene fusions in defined subsets of melanoma.
Turner J; Couts K; Sheren J; Saichaemchan S; Ariyawutyakorn W; Avolio I; Cabral E; Glogowska M; Amato C; Robinson S; Hintzsche J; Applegate A; Seelenfreund E; Gonzalez R; Wells K; Bagby S; Tentler J; Tan AC; Wisell J; Varella-Garcia M; Robinson W
Pigment Cell Melanoma Res; 2017 Jan; 30(1):53-62. PubMed ID: 27864876
[TBL] [Abstract][Full Text] [Related]
2. From genotype to phenotype: Are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements?
Plodkowski AJ; Drilon A; Halpenny DF; O'Driscoll D; Blair D; Litvak AM; Zheng J; Moskowitz CS; Ginsberg MS
Lung Cancer; 2015 Nov; 90(2):321-5. PubMed ID: 26424208
[TBL] [Abstract][Full Text] [Related]
3. ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare.
Zhao W; Choi YL; Song JY; Zhu Y; Xu Q; Zhang F; Jiang L; Cheng J; Zheng G; Mao M
Lung Cancer; 2016 Apr; 94():22-7. PubMed ID: 26973202
[TBL] [Abstract][Full Text] [Related]
4. Identification of NTRK3 Fusions in Childhood Melanocytic Neoplasms.
Wang L; Busam KJ; Benayed R; Cimera R; Wang J; Denley R; Rao M; Aryeequaye R; Mullaney K; Cao L; Ladanyi M; Hameed M
J Mol Diagn; 2017 May; 19(3):387-396. PubMed ID: 28433076
[TBL] [Abstract][Full Text] [Related]
5. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement.
Antonescu CR; Suurmeijer AJ; Zhang L; Sung YS; Jungbluth AA; Travis WD; Al-Ahmadie H; Fletcher CD; Alaggio R
Am J Surg Pathol; 2015 Jul; 39(7):957-67. PubMed ID: 25723109
[TBL] [Abstract][Full Text] [Related]
6. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.
Hutchinson KE; Lipson D; Stephens PJ; Otto G; Lehmann BD; Lyle PL; Vnencak-Jones CL; Ross JS; Pietenpol JA; Sosman JA; Puzanov I; Miller VA; Pao W
Clin Cancer Res; 2013 Dec; 19(24):6696-702. PubMed ID: 24345920
[TBL] [Abstract][Full Text] [Related]
7. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
[TBL] [Abstract][Full Text] [Related]
8. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
[TBL] [Abstract][Full Text] [Related]
9. Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer.
Rogers TM; Arnau GM; Ryland GL; Huang S; Lira ME; Emmanuel Y; Perez OD; Irwin D; Fellowes AP; Wong SQ; Fox SB
Sci Rep; 2017 Feb; 7():42259. PubMed ID: 28181564
[TBL] [Abstract][Full Text] [Related]
10. [ Spectrum of oncogene mutations is different in melanoma subtypes].
Mazurenko NN; Tsyganova IV; Lushnikova AA; Ponkratova DA; Anurova OA; Cheremushkin EA; Mikhailova IN; Demidov LV
Mol Biol (Mosk); 2015; 49(6):1022-9. PubMed ID: 26710785
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigo maligna subtypes.
Lang J; MacKie RM
J Invest Dermatol; 2005 Sep; 125(3):575-9. PubMed ID: 16117801
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.
Saldanha G; Potter L; Daforno P; Pringle JH
Clin Cancer Res; 2006 Aug; 12(15):4499-505. PubMed ID: 16899595
[TBL] [Abstract][Full Text] [Related]
13. Frequent CD30 Expression in an Emerging Group of Mesenchymal Tumors With NTRK, BRAF, RAF1, or RET Fusions.
Kojima N; Mori T; Motoi T; Kobayashi E; Yoshida M; Yatabe Y; Ichikawa H; Kawai A; Yonemori K; Antonescu CR; Yoshida A
Mod Pathol; 2023 Apr; 36(4):100083. PubMed ID: 36788089
[TBL] [Abstract][Full Text] [Related]
14. RET/PTC rearrangement is prevalent in follicular Hürthle cell carcinomas.
de Vries MM; Celestino R; Castro P; Eloy C; Máximo V; van der Wal JE; Plukker JT; Links TP; Hofstra RM; Sobrinho-Simões M; Soares P
Histopathology; 2012 Nov; 61(5):833-43. PubMed ID: 22803838
[TBL] [Abstract][Full Text] [Related]
15. A Performance Comparison of Commonly Used Assays to Detect RET Fusions.
Yang SR; Aypar U; Rosen EY; Mata DA; Benayed R; Mullaney K; Jayakumaran G; Zhang Y; Frosina D; Drilon A; Ladanyi M; Jungbluth AA; Rekhtman N; Hechtman JF
Clin Cancer Res; 2021 Mar; 27(5):1316-1328. PubMed ID: 33272981
[TBL] [Abstract][Full Text] [Related]
16. Low prevalence of RET rearrangements (RET/PTC1, RET/PTC2, RET/PTC3, and ELKS-RET) in sporadic papillary thyroid carcinomas in Taiwan Chinese.
Liu RT; Chou FF; Wang CH; Lin CL; Chao FP; Chung JC; Huang CC; Wang PW; Cheng JT
Thyroid; 2005 Apr; 15(4):326-35. PubMed ID: 15876154
[TBL] [Abstract][Full Text] [Related]
17. Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas.
Wang R; Pan Y; Li C; Zhang H; Garfield D; Li Y; Ye T; Hu H; Luo X; Li H; Zhang Y; Zhang J; Zhou X; Shen L; Pao W; Sun Y; Chen H
J Thorac Oncol; 2014 Jun; 9(6):760-8. PubMed ID: 24481316
[TBL] [Abstract][Full Text] [Related]
18. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma.
Palanisamy N; Ateeq B; Kalyana-Sundaram S; Pflueger D; Ramnarayanan K; Shankar S; Han B; Cao Q; Cao X; Suleman K; Kumar-Sinha C; Dhanasekaran SM; Chen YB; Esgueva R; Banerjee S; LaFargue CJ; Siddiqui J; Demichelis F; Moeller P; Bismar TA; Kuefer R; Fullen DR; Johnson TM; Greenson JK; Giordano TJ; Tan P; Tomlins SA; Varambally S; Rubin MA; Maher CA; Chinnaiyan AM
Nat Med; 2010 Jul; 16(7):793-8. PubMed ID: 20526349
[TBL] [Abstract][Full Text] [Related]
19. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy.
Ross JS; Wang K; Chmielecki J; Gay L; Johnson A; Chudnovsky J; Yelensky R; Lipson D; Ali SM; Elvin JA; Vergilio JA; Roels S; Miller VA; Nakamura BN; Gray A; Wong MK; Stephens PJ
Int J Cancer; 2016 Feb; 138(4):881-90. PubMed ID: 26314551
[TBL] [Abstract][Full Text] [Related]
20. The Frequency and Clinical Implication of ROS1 and RET Rearrangements in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Patients.
Fu S; Liang Y; Lin YB; Wang F; Huang MY; Zhang ZC; Wang J; Cen WJ; Shao JY
PLoS One; 2015; 10(4):e0124354. PubMed ID: 25905642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
